Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivozanib vs Sunitinib in Metastatic Renal Cell Carcinoma (TAURUS)
NCT01673386Phase 2Terminated
- Sponsor
- AVEO Oncology
- Start
- Jul 2012
- Primary completion
- Jan 2014
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of tivozanib in metastatic renal cell carcinoma (mRCC), sponsored by AVEO Oncology. Primary endpoint: Proportion of Subjects Who Prefer Tivozanib Hydrochloride or Sunitinib at 25 weeks. Started Jul 2012; status: terminated.
02
Drugs
tivozanib
03
Conditions
metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on NCT01673386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01673386.